Evidence map›Paper›PMID 26519337›Full record

ArticleDiabetes care2015

Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists.

Avivit Cahn, Itamar Raz, Yosef Kleinman, Ran Balicer, Moshe Hoshen, Nicky Lieberman, Naomi Brenig, Stefano Del Prato, William T Cefalu

Registry-linked trialAbstract read
In one paragraph

Article in Diabetes care, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04841096 (Efficacy and Safety of the Oral Combined Therapy Glimepiride / Vildagliptin / Metformin in Patients With Type 2 Diabetes With Dual Treatment Failure), which is not on this map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04841096 phase3completedstarted 2023, after this paper: background citation

Efficacy and Safety of the Oral Combined Therapy Glimepiride / Vildagliptin / Metformin in Patients With Type 2 Diabetes With Dual Treatment Failure

Ran2023Enrolled162Registered outcomes5Posted comparisons0ConditionsType 2 DiabetesArmsA1=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg), (A2) Glimepiride/Vildagliptin/Metformin, (B2) Glimepiride/Vildagliptin/Metformin, B2=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)
Open the trial in the graph
3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Terminal trajectory of HbAFrontiers in endocrinology · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Considering Insulin Secretory Capacity as Measured by a Fasting C-Peptide/Glucose Ratio in Selecting Glucose-Lowering Medications.Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association · 2022
    Article
  10. Trends in HbAPharmacoepidemiology and drug safety · 2021
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Association of Hemoglobin ADiabetes care · 2018
    Observational
  18. Article
  19. Hemoglobin ADiabetes care · 2017
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Avivit CahnDiabetes Research Center, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Itamar RazDiabetes Research Center, Hadassah Hebrew University Medical Center, Jerusalem, Israel ntv502@netvision.net.il.
Yosef KleinmanDiabetes Unit, Shaare Zedek Medical Center, Bikur Cholim Campus, Jerusalem, Israel.
Ran BalicerClalit Institute for Research, Tel Aviv, Israel.
Moshe HoshenClalit Institute for Research, Tel Aviv, Israel.
Nicky LiebermanClalit Institute for Research, Tel Aviv, Israel.
Naomi BrenigDepartment of Computer Science Education, Michlala Jerusalem College, Jerusalem, Israel.
Stefano Del PratoDepartment of Clinical and Experimental Medicine, University of Pisa School of Medicine, Pisa, Italy.
William T CefaluPennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA.

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI JUDD E SHELLITO · 2012 to 2026
$69.1M
Pregnane and Glycosides and Obesity/llya RaskinP50AT002776 · NCCIH · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI RASKIN, ILYA · 2005 to 2019
$24.9M
NCCIH NIH HHS P50 AT002776NCCIH NIH HHS P50-AT-002776NIGMS NIH HHS 1U54-GM-104940NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

objectiveObservations over the past few years have demonstrated the need to adjust glycemic targets based on parameters pertaining to individual patient characteristics and comorbidities. However, the weight and value given to each parameter will clearly vary depending on the experience of the provider, the characteristics of the patient, and the specific clinical situation. RESEARCH DESIGN AND

methodsTo determine if there is current consensus on a global level with regard to identifying these parameters and their relative importance, we conducted a survey among 244 key worldwide opinion-leading diabetologists. Initially, the physicians were to rank the factors they take into consideration when setting their patients' glycemic target according to their relative importance. Subsequently, six clinical vignettes were presented, and the experts were requested to suggest an appropriate glycemic target. The survey results were used to formulate an algorithm according to which an estimate of the patient's glycemic target based on individualized parameters can be computed. Three additional clinical cases were submitted to a new set of experts for validation of the algorithm.

resultsA total of 151 (61.9%) experts responded to the survey. The parameters "life expectancy" and "risk of hypoglycemia from treatment" were considered to be the most important. "Resources" and "disease duration" ranked the lowest. An algorithm was constructed based on survey results. It was validated by presenting three new cases to 57 leading diabetologists who suggested glycemic targets that were similar to those calculated by the algorithm.

conclusionsThe resultant suggested algorithm is an additional decision-making tool offered to the clinician to supplement clinical decision making when considering a glycemic target for the individual patient with diabetes.

Indexed as

AlgorithmsBlood GlucoseDiabetes Mellitus, Type 2EndocrinologyGoalsHealth Care SurveysHumansPrecision MedicineRiskBlood Glucose

Identifiers

PMID26519337
PMCPMC4657613

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.